Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Cost of revenue

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndCost of revenue (Million JPY)YoY (%)
Dec 31, 2025191+11.94%
Dec 31, 2024171-2.71%
Dec 31, 2023175+2.18%
Dec 31, 2022172+26.71%
Dec 31, 2021135-29.54%
Dec 31, 2020192-7.44%
Dec 31, 2019208-17.20%
Dec 31, 2018251+12.67%
Dec 31, 2017223-12.55%
Dec 31, 2016254-5.63%
Dec 31, 2015270+15.73%
Dec 31, 2014233

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat